Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > AGN to use Stroke research to accelerate TBI study
View:
Post by StockHawk1 on Feb 23, 2023 3:52pm

AGN to use Stroke research to accelerate TBI study

Algernon Pharmaceuticals' (AGN.c AGNPF) subsidiary, AGN Neuro, has added a new clinical research program to investigate treating Traumatic Brain Injury with DMT. 


AGN hopes to use data from its ongoing DMT-Stroke study to accelerate directly into a Phase 2 TBI study in Q4, 2023. 


https://ca.finance.yahoo.com/news/algernon-neuroscience-initiates-traumatic-brain-120000497.html

 
Comment by waves1 on Feb 24, 2023 4:25pm
AGN is positioning itself at the forefront of DMT research as they now have two studies investigating its use - as the industry around psychedelics continues to develop, AGN could face some solid exposure from this imo. 
Algernon Pharmaceuticals Inc